Results of Shareholder Analysis

Summary by AI ^BETAClose X

CRISM Therapeutics Corporation has announced the results of an independent shareholder register analysis as of December 31, 2025, revealing significant holdings by Andrew Webb with 14.10%, Christopher McConville with 9.65%, Brian Murray with 9.49%, David Lawton with 9.28%, and Zeus Dynamic Opportunities Fund with 3.67%. Following recent share issuances, neither Linista Group Inc. nor Spreadex hold a disclosable stake. The company is preparing to initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed™ in glioblastoma patients in Q1 2026.

Disclaimer*

CRISM Therapeutics Corporation

09 January 2026

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Results of Shareholder Analysis

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third-party shareholder register analysis, that as at 31 December 2025, the Company is aware of the following significant shareholders, being those with an interest in 3% or more of the ordinary share capital of the Company ("Ordinary Shares").

Shareholder	No. of Ordinary Shares	% interest in the ordinary share capital of the Company
Andrew Webb	7,297,190	14.10%
Christopher McConville	4,992,033	9.65%
Brian Murray	4,908,700	9.49%
David Lawton	4,802,416	9.28%
Zeus Dynamic Opportunities Fund	1,900,000	3.67%

Following the issue of the placing and retail offer shares (as announced on 10 and 15 December 2025 respectively) neither Linista Group Inc. or Spreadex hold a disclosable shareholding in the Company.

-Ends-

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, CEO Chris McConville, CSO	Richard Morrison Vadim Alexandre Adam Cowl	Mark Court / Jamie Hooper CRISM@buchanancomms.co.uk
via Burson Buchanan	+44 (0) 20 3470 0470	+44 (0) 20 7466 5000

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed™ in patients with surgically resectable glioblastoma in Q1 2026.

For more information please visit: https://www.crismtherapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END